|Bid||24.33 x 0|
|Ask||24.34 x 0|
|Day's Range||24.24 - 24.63|
|52 Week Range||21.41 - 34.31|
|Beta (5Y Monthly)||0.13|
|PE Ratio (TTM)||24.45|
|Earnings Date||Nov 05, 2020|
|Forward Dividend & Yield||0.36 (1.48%)|
|Ex-Dividend Date||Oct 26, 2020|
|1y Target Est||25.56|
Moody's Investors Service ("Moody's") has today affirmed the Ba3 corporate family rating (CFR) of Spanish healthcare company Grifols S.A. (Grifols) and its Ba3-PD probability of default rating. At the same time, Moody's has affirmed the Ba2 senior secured ratings of Grifols, Grifols World Wide Operations Ltd. and Grifols World Wide Operations USA, Inc. Moody's has also affirmed Grifols' B2 senior unsecured rating.
Let's see if Grifols (GRFS) stock is a good choice for value-oriented investors right now from multiple angles.
Grifols (MCE: GRF) (MCE: GRF.P) (NASDAQ: GRFS), a global healthcare company and one of the world's leading producers of plasma-derived medicines with more than 100 years of history contributing to improve people's health and well-being, has been recognized among the world's most sustainable companies by the Dow Jones Sustainability Index (DJSI), the largest global sustainability index and an international benchmark for socially responsible investors.